poisar

Stock

Pacira BioSciences, Inc. PCRX

$25.77-0.54%

Overview

PCRX market data

Price History

PCRX price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
199.62
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$0.16
Diluted earnings per share over the trailing twelve months.
Beta
0.25
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$18.80 – $27.64
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1K · P/B 1.61 · P/S 1.40.

Company news

8 captured
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026Globenewswire Inc · Jul 22, 2026, 12:15 PM
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Globenewswire Inc · Jul 8, 2026, 12:15 PM
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price TargetBenzinga · Jul 1, 2026, 12:25 PM
Pacira BioSciences Says UnitedHealthcare Now Provides Separate Reimbursement For EXPAREL Across Outpatient Settings, Including Hospital Outpatient Departments And Ambulatory Surgery CentersBenzinga · Jul 1, 2026, 12:10 PM
Pacira BioSciences Divests Iovera To Zimmer Biomet For Up To $140MBenzinga · Jun 30, 2026, 11:40 AM
8-K filing — Pacira BioSciences, Inc. (PCRX)SEC EDGAR · Jun 30, 2026, 11:31 AM
Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsightGlobenewswire Inc · Jun 15, 2026, 5:15 PM
Pacira BioSciences Announces Findings From Real-World Study Evaluating Outcomes Associated With Use Of EXPAREL Following Outpatient Total Shoulder Arthroplasty In Medicare Advantage PatientsBenzinga · May 27, 2026, 12:04 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock